Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
A variety of applications, systems, methods and constructs are implemented for use in connection with screening of ion-channel modulators. Consistent with one such system, drug candidates are screened to identify their effects on cell membrane ion channels and pumps. The system includes screening cells having light responsive membrane ion switches, voltage-gated ion switches and fluorescence producing voltage sensors. A chemical delivery device introduces the drug candidates to be screened. An optical delivery device activates the light responsive ion switches. An optical sensor monitors fluorescence produced by the voltage sensors. A processor processes data received from the optical sensor. A memory stores the data received from the optical sensor.
1. A method for screening test drugs to identify their effects on cell membrane voltage-gated ion channel, the method comprising: a) contacting a mammalian cell with a test drug, wherein the cell: is genetically modified to express a heterologous, microbial light-responsive ChR2 ion channel comprising an amino acid sequence having at least 75% amino acid sequence identity to SEQ ID NO: 1, wherein the heterologous ChR2 ion channel, when activated by light, results in a change in the voltage in the cell membrane; wherein the cell comprises: i) a voltage-gated ion channel that causes a change in the intracellular concentration of an ion in response to the light-induced change in voltage; and ii) an indicator that produces a fluorescent signal in response to a change in the intracellular concentration of the ion; b) activating the heterologous, microbial light responsive ChR2 ion channel with light; c) detecting a fluorescent signal produced by the indicator; processing data received from the indicator; and storing the processed data received from the indicator, wherein a change in the signal produced by the indicator in the presence of the test drug, compared to the signal produced in the absence of the test drug, indicates that the test drug is a candidate drug that affects the voltage-gated ion channel.
2. The method of claim 1 , wherein the voltage-gated ion channel is a Ca 2+ channel, a K + channel, a Cl − channel, or a Na + channel.
3. The method of claim 1 , wherein the voltage-gated ion channel is a Ca 2+ channel, and wherein the fluorescence producing indicator is a calcium-sensitive dye.
4. The method of claim 1 , further comprising introducing a plurality of test drugs to respective wells of an array of wells that each contain the mammalian cells and detecting light from respective wells from the array of wells using an array of optical sensors for detecting light.
5. The method of claim 1 , wherein the light-responsive ChR2 ion channel comprises an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:1.
6. The method of claim 1 , wherein the light-responsive ChR2 ion channel comprises an amino acid sequence having at least 90% amino acid sequence identity to SEQ ID NO:1.
7. The method of claim 1 , wherein the light-responsive ChR2 ion channel comprises an amino acid sequence having at least 95% amino acid sequence identity to SEQ ID NO:1.
8. The method of claim 1 , wherein the cell is an immortalized cell line.
9. The method of claim 1 , wherein the indicator is a voltage-sensitive dye.
10. A method for screening test drugs to identify their effects on cell membrane voltage-gated ion channel, the method comprising:
a) contacting a mammalian cell with a test drug, wherein the cell is genetically modified to express a heterologous, microbial light-responsive ion channel and a heterologous, microbial light-responsive ion pump that, when activated by light, results in a change in the voltage in the cell membrane; wherein the cell comprises:
i) a voltage-gated ion channel that causes a change in the intracellular concentration of an ion in response to the light-induced change in voltage; and
ii) an indicator that produces a fluorescent signal in response to a change in the intracellular concentration of the ion;
b) activating the heterologous, microbial light responsive ion channel or heterologous, microbial light-responsive ion pump with light;
c) detecting a fluorescent signal produced by the indicator;
processing data received from the indicator; and
storing the processed data received from the indicator, wherein a change in the signal produced by the indicator in the presence of the test drug, compared to the signal produced in the absence of the test drug, indicates that the test drug is a candidate drug that affects the voltage-gated ion channel.
11. The method of claim 10 , wherein the light-responsive ion channel is a ChR2 ion channel comprising an amino acid sequence having at least 75% amino acid sequence identity to SEQ ID NO:1.
12. The method of claim 10 , wherein the light-responsive ion pump is an NpHR ion pump.
13. The method of claim 10 , wherein the voltage-gated ion channel is a Ca 2+ channel, a K + channel, a Cl − channel, or a Na + channel.
14. The method of claim 10 , wherein the voltage-gated ion channel is a Ca 2+ channel, and wherein the fluorescence producing indicator is a calcium-sensitive dye.
15. The method of claim 10 , wherein the light-responsive ion channel is a ChR2 ion channel comprising an amino acid sequence having at least 85% amino acid sequence identity to SEQ ID NO:1.
16. The method of claim 10 , wherein the light-responsive ion channel is a ChR2 ion channel comprising an amino acid sequence having at least 90% amino acid sequence identity to SEQ ID NO:1.
17. The method of claim 10 , wherein the light-responsive ion channel is a ChR2 ion channel comprising an amino acid sequence having at least 95% amino acid sequence identity to SEQ ID NO:1.
18. The method of claim 10 , wherein the cell is an immortalized cell line.
19. The method of claim 10 , wherein the indicator is a voltage-sensitive dye.